Market Cap 12.06B
Revenue (ttm) 943.71M
Net Income (ttm) -381.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -40.41%
Debt to Equity Ratio 0.00
Volume 1,241,100
Avg Vol 1,818,058
Day's Range N/A - N/A
Shares Out 165.26M
Stochastic %K 7%
Beta 0.37
Analysts Strong Sell
Price Target $103.55

Company Profile

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult pat...

Industry: Biotechnology
Sector: Healthcare
Phone: 760 931 9200
Address:
2855 Gazelle Court, Carlsbad, United States
MarketBeat
MarketBeat May. 26 at 12:08 AM
https://marketbeat.com/a/8674537/ $IONS Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts
0 · Reply
AIBioScanner
AIBioScanner May. 25 at 6:30 AM
$IONS AI-Based Findings on IONS After running IONS through my AI-driven quantitative framework, the stock is in a uptrend with price holding above both moving averages with constructive momentum. IONS is trading around $75.56, above both the 20-day (~$74.98) and 50-day (~$74.25) moving averages — indicating sustained buying interest and improving structure. Key signals: • Trading above both MAs — uptrend • MACD positive (0.04) — bullish momentum • Range between ~$71.78 support and ~$81.96 resistance 1-Month Outlook: Base scenario: consolidation near $71.78–$79.34 Breakout above $79.34 could open a move toward $92.83 Breakdown below $71.78 may extend further downside toward $58.86 Structure is bullish. Requires continued volume confirmation to extend trend. Not financial advice.
0 · Reply
Fingerlickengood
Fingerlickengood May. 18 at 8:57 PM
$CDXS $NVS $IONS $AMGN "With phase 3 data from studies on Lp(a)s pelacarsen (TQJ230; Novartis) and olpasiran (Amgen) expected in the near term, quantifying the eligible population and projecting preventable events is a timely and policy-relevant contribution. If these therapies deliver even modest RRR in outcomes trials, the public health dividend could be substantial." -Pelacarsen is an experimental antisense oligonucleotide drug designed to lower lipoprotein(a) (Lp(a)) levels in patients with cardiovascular disease. It was developed by Ionis Pharmaceuticals and Novartis. -Olpasiran is an investigational small interfering RNA (siRNA) therapy developed by Arrowhead Pharmaceuticals and licensed worldwide by Amgen. Olpasiran is under investigation to reduce major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease (ASCVD) and elevated Lp(a) concentrations. https://www.ajmc.com/view/more-than-5-million-us-adults-could-benefit-from-lp-a--targeted-therapies
0 · Reply
MarketBeat
MarketBeat May. 18 at 10:05 AM
https://marketbeat.com/a/8660902/ $IONS Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference
0 · Reply
DonCorleone77
DonCorleone77 May. 14 at 11:12 AM
$IONS $BIIB Ionis announces Biogen's CELIA study did not meet primary endpoint Ionis Pharmaceuticals (IONS) announced that its partner, Biogen (BIIB), shared compelling topline results from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide, ASO, therapy targeting tau, in individuals with early Alzheimer's disease, AD. The Celia results provide the first evidence from a randomized Phase 2 study of a tau-directed therapy demonstrating both robust biomarker impact and cognitive benefit in early AD. Key highlights: Based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development; CELIA did not meet its primary endpoint assessing dose response; reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study; Pre-specified analyses of cognitive endpoints demonstrated slowing of clinical decline across all studied doses, particularly at the lowest dose; The safety and tolerability profile of diranersen was generally consistent with the Phase 1b study.
2 · Reply
S144
S144 May. 13 at 5:52 AM
$IONS Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript https://seekingalpha.com/article/4903347-ionis-pharmaceuticals-inc-ions-presents-at-bank-of-america-global-healthcare-conference-2026 Btw: IONS is +126% in 1Y
0 · Reply
CapitalMonk
CapitalMonk May. 11 at 10:52 PM
$IONS Price: $75.38 (-0.44%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.14% RSI: 52.9 | Momentum: Moderate Volume: -17.5% vs avg Volatility: 1.47% Support: $71.18 | Resistance: $77.76 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 2:53 PM
$IONS Current Stock Price: $76.79 Contracts to trade: $77.5 IONS May 15 2026 Call Entry: $0.35 Exit: $0.68 ROI: 96% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 2:32 PM
$IONS Current Stock Price: $76.43 Contracts to trade: $77.5 IONS May 15 2026 Call Entry: $0.90 Exit: $1.70 ROI: 89% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
onefryshy
onefryshy May. 5 at 7:38 PM
$IONS I especially like the fact that nobody is following this stock because I think it could be bought out at some point.
5 · Reply
Latest News on IONS
Ionis to host 2026 virtual Annual Meeting of Stockholders

May 4, 2026, 7:05 AM EDT - 4 weeks ago

Ionis to host 2026 virtual Annual Meeting of Stockholders


Ionis to present at upcoming investor conferences

May 1, 2026, 7:05 AM EDT - 4 weeks ago

Ionis to present at upcoming investor conferences


Ionis Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 5 weeks ago

Ionis Pharmaceuticals Earnings Call Transcript: Q1 2026


Ionis Pharmaceuticals Earnings release: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 5 weeks ago

Ionis Pharmaceuticals Earnings release: Q1 2026


Ionis Pharmaceuticals Slides: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 5 weeks ago

Ionis Pharmaceuticals Slides: Q1 2026


Ionis Pharmaceuticals Quarterly report: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 5 weeks ago

Ionis Pharmaceuticals Quarterly report: Q1 2026


Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c)

2026-04-29T11:41:17.000Z - 5 weeks ago

Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c)


Ionis Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

Ionis Pharmaceuticals Proxy statement: Proxy filing


Ionis Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

Ionis Pharmaceuticals Proxy statement: Proxy filing


Ionis Pharmaceuticals initiated with a Buy at Canaccord

2026-04-21T09:05:11.000Z - 6 weeks ago

Ionis Pharmaceuticals initiated with a Buy at Canaccord


Ionis Pharmaceuticals initiated with a Buy at Canaccord

2026-04-20T20:43:15.000Z - 6 weeks ago

Ionis Pharmaceuticals initiated with a Buy at Canaccord


Ionis to hold first quarter 2026 financial results webcast

Apr 15, 2026, 7:05 AM EDT - 7 weeks ago

Ionis to hold first quarter 2026 financial results webcast


Ionis announces changes to Board of Directors

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Ionis announces changes to Board of Directors


Ionis Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 25, 2026, 8:30 AM EST - 3 months ago

Ionis Pharmaceuticals Earnings Call Transcript: Q4 2025


Ionis Pharmaceuticals Annual report: Q4 2025

Feb 25, 2026, 8:30 AM EST - 3 months ago

Ionis Pharmaceuticals Annual report: Q4 2025


Ionis Pharmaceuticals Earnings release: Q4 2025

Feb 25, 2026, 8:30 AM EST - 3 months ago

Ionis Pharmaceuticals Earnings release: Q4 2025


Ionis Pharmaceuticals Slides: Q4 2025

Feb 25, 2026, 8:30 AM EST - 3 months ago

Ionis Pharmaceuticals Slides: Q4 2025


Biogen Completes Acquisition of Alcyone Therapeutics

Nov 14, 2025, 4:05 PM EST - 7 months ago

Biogen Completes Acquisition of Alcyone Therapeutics

BIIB


Ionis Pharmaceuticals Transcript: Study Update

Nov 8, 2025, 3:00 PM EST - 7 months ago

Ionis Pharmaceuticals Transcript: Study Update


Ionis Pharmaceuticals Slides: Study Update

Nov 8, 2025, 3:00 PM EST - 7 months ago

Ionis Pharmaceuticals Slides: Study Update


Ionis Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 29, 2025, 11:30 AM EDT - 7 months ago

Ionis Pharmaceuticals Earnings Call Transcript: Q3 2025


Ionis Pharmaceuticals Quarterly report: Q3 2025

Oct 29, 2025, 11:30 AM EDT - 7 months ago

Ionis Pharmaceuticals Quarterly report: Q3 2025


Ionis Pharmaceuticals Earnings release: Q3 2025

Oct 29, 2025, 11:30 AM EDT - 7 months ago

Ionis Pharmaceuticals Earnings release: Q3 2025


Ionis Pharmaceuticals Slides: Q3 2025

Oct 29, 2025, 11:30 AM EDT - 7 months ago

Ionis Pharmaceuticals Slides: Q3 2025


Ionis to hold third quarter 2025 financial results webcast

Oct 16, 2025, 7:05 AM EDT - 8 months ago

Ionis to hold third quarter 2025 financial results webcast


Ionis Pharmaceuticals Transcript: Innovation Day 2025

Oct 7, 2025, 8:30 AM EDT - 8 months ago

Ionis Pharmaceuticals Transcript: Innovation Day 2025


Ionis Pharmaceuticals Press release: FY 2025

Oct 7, 2025, 8:30 AM EDT - 8 months ago

Ionis Pharmaceuticals Press release: FY 2025


Ionis Pharmaceuticals Slides: FY 2025

Oct 7, 2025, 8:30 AM EDT - 8 months ago

Ionis Pharmaceuticals Slides: FY 2025


Ionis' brain disorder drug shows promise in clinical trial

Sep 22, 2025, 7:10 AM EDT - 9 months ago

Ionis' brain disorder drug shows promise in clinical trial


Ionis to host investors and analysts for Innovation Day 2025

Sep 8, 2025, 4:00 PM EDT - 9 months ago

Ionis to host investors and analysts for Innovation Day 2025


Is The 35% Rally In IONS Stock Just The Beginning?

Sep 3, 2025, 10:41 AM EDT - 9 months ago

Is The 35% Rally In IONS Stock Just The Beginning?


Ionis Pharmaceuticals Transcript: Study Result

Sep 2, 2025, 8:30 AM EDT - 9 months ago

Ionis Pharmaceuticals Transcript: Study Result


Ionis Pharmaceuticals Press release: Study Result

Sep 2, 2025, 8:30 AM EDT - 9 months ago

Ionis Pharmaceuticals Press release: Study Result


Ionis Pharmaceuticals Slides: Study Result

Sep 2, 2025, 8:30 AM EDT - 9 months ago

Ionis Pharmaceuticals Slides: Study Result


Ionis Pharmaceuticals Transcript: FDA Announcement

Aug 21, 2025, 12:15 PM EDT - 10 months ago

Ionis Pharmaceuticals Transcript: FDA Announcement


Ionis Pharmaceuticals Press release: FDA Announcement

Aug 21, 2025, 12:15 PM EDT - 10 months ago

Ionis Pharmaceuticals Press release: FDA Announcement


Ionis Pharmaceuticals Slides: FDA Announcement

Aug 21, 2025, 12:15 PM EDT - 10 months ago

Ionis Pharmaceuticals Slides: FDA Announcement


US FDA approves Ionis' drug for rare genetic disorder

Aug 21, 2025, 11:58 AM EDT - 10 months ago

US FDA approves Ionis' drug for rare genetic disorder


Ionis Pharmaceuticals Earnings Call Transcript: Q2 2025

Jul 30, 2025, 11:30 AM EDT - 11 months ago

Ionis Pharmaceuticals Earnings Call Transcript: Q2 2025


Ionis Pharmaceuticals Quarterly report: Q2 2025

Jul 30, 2025, 11:30 AM EDT - 11 months ago

Ionis Pharmaceuticals Quarterly report: Q2 2025


Ionis Pharmaceuticals Earnings release: Q2 2025

Jul 30, 2025, 11:30 AM EDT - 11 months ago

Ionis Pharmaceuticals Earnings release: Q2 2025


Ionis Pharmaceuticals Slides: Q2 2025

Jul 30, 2025, 11:30 AM EDT - 11 months ago

Ionis Pharmaceuticals Slides: Q2 2025


MarketBeat
MarketBeat May. 26 at 12:08 AM
https://marketbeat.com/a/8674537/ $IONS Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts
0 · Reply
AIBioScanner
AIBioScanner May. 25 at 6:30 AM
$IONS AI-Based Findings on IONS After running IONS through my AI-driven quantitative framework, the stock is in a uptrend with price holding above both moving averages with constructive momentum. IONS is trading around $75.56, above both the 20-day (~$74.98) and 50-day (~$74.25) moving averages — indicating sustained buying interest and improving structure. Key signals: • Trading above both MAs — uptrend • MACD positive (0.04) — bullish momentum • Range between ~$71.78 support and ~$81.96 resistance 1-Month Outlook: Base scenario: consolidation near $71.78–$79.34 Breakout above $79.34 could open a move toward $92.83 Breakdown below $71.78 may extend further downside toward $58.86 Structure is bullish. Requires continued volume confirmation to extend trend. Not financial advice.
0 · Reply
Fingerlickengood
Fingerlickengood May. 18 at 8:57 PM
$CDXS $NVS $IONS $AMGN "With phase 3 data from studies on Lp(a)s pelacarsen (TQJ230; Novartis) and olpasiran (Amgen) expected in the near term, quantifying the eligible population and projecting preventable events is a timely and policy-relevant contribution. If these therapies deliver even modest RRR in outcomes trials, the public health dividend could be substantial." -Pelacarsen is an experimental antisense oligonucleotide drug designed to lower lipoprotein(a) (Lp(a)) levels in patients with cardiovascular disease. It was developed by Ionis Pharmaceuticals and Novartis. -Olpasiran is an investigational small interfering RNA (siRNA) therapy developed by Arrowhead Pharmaceuticals and licensed worldwide by Amgen. Olpasiran is under investigation to reduce major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease (ASCVD) and elevated Lp(a) concentrations. https://www.ajmc.com/view/more-than-5-million-us-adults-could-benefit-from-lp-a--targeted-therapies
0 · Reply
MarketBeat
MarketBeat May. 18 at 10:05 AM
https://marketbeat.com/a/8660902/ $IONS Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference
0 · Reply
DonCorleone77
DonCorleone77 May. 14 at 11:12 AM
$IONS $BIIB Ionis announces Biogen's CELIA study did not meet primary endpoint Ionis Pharmaceuticals (IONS) announced that its partner, Biogen (BIIB), shared compelling topline results from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide, ASO, therapy targeting tau, in individuals with early Alzheimer's disease, AD. The Celia results provide the first evidence from a randomized Phase 2 study of a tau-directed therapy demonstrating both robust biomarker impact and cognitive benefit in early AD. Key highlights: Based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development; CELIA did not meet its primary endpoint assessing dose response; reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study; Pre-specified analyses of cognitive endpoints demonstrated slowing of clinical decline across all studied doses, particularly at the lowest dose; The safety and tolerability profile of diranersen was generally consistent with the Phase 1b study.
2 · Reply
S144
S144 May. 13 at 5:52 AM
$IONS Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript https://seekingalpha.com/article/4903347-ionis-pharmaceuticals-inc-ions-presents-at-bank-of-america-global-healthcare-conference-2026 Btw: IONS is +126% in 1Y
0 · Reply
CapitalMonk
CapitalMonk May. 11 at 10:52 PM
$IONS Price: $75.38 (-0.44%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.14% RSI: 52.9 | Momentum: Moderate Volume: -17.5% vs avg Volatility: 1.47% Support: $71.18 | Resistance: $77.76 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 2:53 PM
$IONS Current Stock Price: $76.79 Contracts to trade: $77.5 IONS May 15 2026 Call Entry: $0.35 Exit: $0.68 ROI: 96% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 2:32 PM
$IONS Current Stock Price: $76.43 Contracts to trade: $77.5 IONS May 15 2026 Call Entry: $0.90 Exit: $1.70 ROI: 89% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
onefryshy
onefryshy May. 5 at 7:38 PM
$IONS I especially like the fact that nobody is following this stock because I think it could be bought out at some point.
5 · Reply
Ccg_
Ccg_ May. 4 at 11:17 PM
$IONS what is that ah?
0 · Reply
Monkey7779192
Monkey7779192 May. 2 at 5:26 PM
$IONS Odds of approval in June 30? Has puts huge volume.
0 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 5:22 PM
$IONS Current Stock Price: $75.54 Contracts to trade: $75.0 IONS May 15 2026 Call Entry: $1.55 Exit: $2.57 ROI: 66% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
IN0V8
IN0V8 Apr. 30 at 2:21 PM
$IONS Buy Barclays raises target price to $115 from $106 H.C. Wainwright raises target price to $125 from $120 Leerink Partners raises target to $114 from $111 Stifel raises target price to $86 from $83
0 · Reply
Djohn2012
Djohn2012 Apr. 29 at 2:57 PM
$IONS Huge beat! Why is this not flying?
1 · Reply
jcooptechit
jcooptechit Apr. 29 at 1:43 PM
$CELZ TIGHTENING AND NEXT LEG COULD IGNITE FAST CELZ is tightening into a clean bullish structure with a defined base and rising trend: this is where momentum setups begin. 📊 TECHNICAL BREAKDOWN: ▫️ Demand Zone: $1.90 – $2.05 (strong accumulation + multiple holds) ▫️ Support: $2.05 - $2.16 ▫️ Pivot Zone: $2.16 – $2.32 ▫️ Resistance: $2.50 ▫️ Next Resistance: $2.72 ▫️ Breakout Level: $2.72+ 📈 CHART STRUCTURE: • Higher lows forming/ uptrend developing • Descending trendline already broken • Consolidation above demand = strong base • Price holding key mid-range levels 🧠 KEY CATALYSTS: ▫️ Ongoing clinical trials (CELZ-201) ▫️ Positive interim data already reported ▫️ Upcoming updates = news-driven momentum potential ▫️ Regenerative medicine narrative ($90B+ market) CELZ sitting at a key inflection. watch $2.32 - $2.72 closely. This is where the next move can accelerate. Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $REGN $VRTX $ALNY $IONS
0 · Reply
Fingerlickengood
Fingerlickengood Apr. 29 at 1:18 PM
$CDXS $RNA $MRK $IONS https://www.globenewswire.com/news-release/2026/04/29/3283814/24825/en/Codexis-to-share-RNA-manufacturing-advances-at-TIDES-USA.html
2 · Reply
JFais
JFais Apr. 29 at 11:58 AM
$IONS was on the fence but missed this one entirely, as good as a value setup in biotech as there ever was
1 · Reply
JFais
JFais Apr. 29 at 11:56 AM
$IONS increasing annual peak sales for olezarsen from $2 billion to $3 billion- reflects increasing confidence in the sHTG market opportunity (bodes well for $ARWR's plozasiran/Redemplo)
0 · Reply
JFais
JFais Apr. 29 at 11:47 AM
$KALV- sold too soon, congrats to longs on the Chiesi buyout 👏($1.9B valuation a solid exit considering coming competition like $PHVS $IONS)
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 29 at 11:08 AM
$IONS Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.56 up 39.78% YoY • Reported revenue of $246M up 86.91% YoY • Ionis improved its full year 2026 total revenue guidance to $875-900 million and lowered its non-GAAP operating loss guidance to $425-475 million, maintaining cash, cash equivalents, and short-term investments above $1.6 billion.
0 · Reply
zerodayrounder
zerodayrounder Apr. 28 at 7:57 PM
from $GSK Q4 report 2 major product approvals expected -- bepirovirsen PDUFA date set today for October 26, 2026 --- partner $IONS $12B market cap too big to acquire tebipenem is next June 18.. with $SPRO $160 million market cap out of the readouts -- jemperli (contract dispute with $ANAB) one would think GSK would want to fully own blockbusters
0 · Reply